Pharvaris Presents Clinical And Non-Clinical Data Supporting HAE Development Program At The 2024 ACAAI Annual Scientific Meeting
Portfolio Pulse from Benzinga Newsdesk
Pharvaris (NASDAQ:PHVS) is set to present clinical and non-clinical data supporting its HAE development program at the 2024 ACAAI Annual Scientific Meeting. The company is focused on developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE).
October 24, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pharvaris is presenting data on its HAE development program at the 2024 ACAAI Meeting, highlighting its progress in oral bradykinin B2 receptor antagonists.
The presentation of clinical and non-clinical data at a major scientific meeting could positively impact Pharvaris by increasing visibility and credibility in the scientific community, potentially leading to increased investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90